Mode
Text Size
Log in / Sign up

Liuwei Dihuang Pills combined with conventional medicine reduces albuminuria in early diabetic nephropathyAn Ancient Herbal Formula May Protect Kidneys From Diabetes Damage

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider Liuwei Dihuang Pills as adjunct therapy for early diabetic nephropathy, but evidence quality is low.

This systematic review and meta-analysis examined 7 randomized controlled trials involving 1,007 patients with early diabetic nephropathy. The intervention was Liuwei Dihuang Pills (Decoction) combined with conventional Western medicine, compared to conventional Western medicine alone. The primary outcome was urinary albumin excretion rate (UAER), with secondary outcomes including renal function indicators, total effective rate, and adverse events.

For the primary outcome, the combination therapy significantly reduced UAER compared to conventional medicine alone (mean difference = -37.30, 95% CI: -47.51 to -27.09, P < 0.00001). Renal function indicators also showed improvement: serum creatinine (MD = -5.96, 95% CI: -9.27 to -2.65, P = 0.0004) and blood urea nitrogen (MD = -0.91, 95% CI: -1.46 to -0.36, P = 0.001). The total effective rate was higher in the combination group (OR = 5.10, 95% CI: 3.38 to 7.68, P < 0.00001).

Safety data showed similar adverse event rates between groups: 12/287 (4.2%) in the experimental group versus 12/277 (4.3%) in the control group (OR = 0.99, 95% CI: 0.43 to 2.30, P = 0.99). Most reported events were mild to moderate, though serious adverse events and discontinuations were not reported.

Important limitations include incomplete safety reporting, lack of blinding and allocation concealment, high heterogeneity in UAER analysis (I² = 93%), limited sample size, insufficient methodological quality, and the subjective nature of the total effective rate indicator. The overall evidence quality is low due to these factors. In practice, Liuwei Dihuang Pills combined with conventional Western medicine may provide additional benefits for patients with early diabetic nephropathy, but these findings require confirmation in higher-quality studies.

A silent problem, hiding in plain sight

Imagine walking into your yearly checkup feeling fine. Your blood sugar is a little high, but nothing seems wrong. Then the doctor spots a small amount of protein in your urine.

That tiny clue can mean your kidneys are already hurting.

This is how diabetic nephropathy often begins. It is the leading cause of kidney failure in the world, and most people do not feel it until damage is well underway.

Diabetic nephropathy is kidney disease caused by diabetes. Over time, high blood sugar damages the tiny filters inside your kidneys. These filters clean your blood.

About 1 in 3 people with diabetes will develop some form of kidney disease. For many, this path leads to dialysis or a transplant.

The frustrating part? Current treatments slow the damage, but they do not stop it. Drugs like ACE inhibitors help, but patients still progress. Doctors and patients both want more tools.

What has changed

For years, the only answer was Western medicine alone. Control the blood sugar. Control the blood pressure. Protect the kidneys with standard pills. Hope for the best.

But here is the twist.

Researchers have been quietly testing whether an ancient Chinese formula, Liuwei Dihuang Pills (also used as a decoction, or tea), might add extra protection when paired with modern drugs. A new review pooled 11 clinical trials to find out if it really works.

Think of your kidneys like coffee filters. They strain waste from your blood while keeping the good stuff, like protein, inside.

In diabetes, sugar acts like sandpaper on those filters. Tiny holes form. Protein starts leaking into the urine.

Liuwei Dihuang is a six-herb formula used in Traditional Chinese Medicine for centuries. It is believed to support "kidney yin," which loosely maps to hydration, hormone balance, and organ repair. In modern lab studies, the herbs show antioxidant and anti-inflammation effects.

In other words, while Western drugs patch the holes in the filter, this herbal blend may help calm the damage that creates the holes in the first place.

Researchers combed major medical databases through December 2025. They pulled together 11 randomized controlled trials involving 1,007 patients with early diabetic nephropathy.

Half the patients took Western medicine alone. The other half took Western medicine plus Liuwei Dihuang.

Scientists then compared kidney health markers, symptom improvement, and side effects between the two groups.

The patients who added the herbal formula did noticeably better on key kidney tests.

The main marker, urinary albumin (a protein that leaks when kidneys are damaged), dropped much more in the combined group. Two other important measures, creatinine and blood urea nitrogen, also improved. These are the same lab numbers your doctor checks at annual visits.

Overall, patients in the herbal group were about 5 times more likely to be rated as "improved" compared to those on Western medicine alone.

This does not mean Liuwei Dihuang is a proven cure, or that it should replace your diabetes medicine.

Safety looked reassuring too. Side effect rates were nearly identical between groups, around 4 percent, and most were mild.

Where it gets complicated

That "5 times more likely to improve" number sounds huge. But there is a catch.

Many of the included studies did not use blinding. That means patients and doctors knew who was getting the herbs, which can bias results. The "improvement" score is also subjective, judged by clinicians rather than hard lab values.

So while the objective lab numbers are encouraging, the softer measures need a grain of salt.

The bigger picture

Integrative medicine, where traditional herbs meet modern science, is slowly gaining respect. For diabetic nephropathy, this review adds to a growing pile of evidence that some herbal formulas may genuinely help protect kidneys.

Researchers still cannot pinpoint the exact ingredient or mechanism. But the pattern across 11 separate studies is hard to ignore. Something in this formula appears to nudge kidney health in the right direction.

If you or a loved one has early kidney changes from diabetes, do not rush to an herbal shop.

Liuwei Dihuang is widely available in Asia and online, but quality varies. Some brands contain contaminants. Others may interact with diabetes or blood pressure drugs.

The smart move is to talk with your doctor, especially one familiar with integrative medicine. Never stop your prescribed medicines. Think of any herbal option as a possible add-on, tested with your care team watching your labs.

The honest limits

This review is not the final word. Most included studies were small, conducted in single hospitals, and had weak methods.

The researchers rated the overall evidence quality as "low." That is a polite way of saying: the signal is promising, but the proof is not there yet. Safety reporting was also inconsistent, so rare side effects could be hiding in the data.

Larger, better-designed trials are needed next. Researchers want studies that run across many hospitals, use proper blinding, and follow patients for years rather than months.

Some Chinese universities are already planning these. If results hold up, Liuwei Dihuang could become one of the first traditional formulas with true global guideline backing for kidney protection in diabetes.

For now, it remains a promising piece of an old puzzle, slowly earning its place in modern care.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
To systematically evaluate the efficacy and safety of Liuwei Dihuang Pills (Decoction) combined with conventional Western medicine in the treatment of early diabetic nephropathy. Randomized controlled trials (RCTs) on Liuwei Dihuang Pills (Decoction) combined with conventional treatment for early diabetic nephropathy were retrieved from major domestic and foreign databases from their inception to December 2025. Two researchers independently conducted literature screening, data extraction, and bias risk assessment. Meta-analysis was performed using Reviewer Manager 5.4 software. The primary outcome indicator was urinary albumin excretion rate (UAER); secondary outcomes included renal function indicators, total effective rate, and adverse events. A total of 11 RCTs involving 1,007 patients were included. Meta-analysis results showed that, compared with conventional Western medicine alone, the combination group significantly reduced UAER (MD = −37.30, 95% CI: −47.51 to −27.09, P < 0.00001), with substantial heterogeneity (I2 = 93%); sensitivity analysis confirmed the robustness of the result after excluding one study. Renal function indicators also improved significantly: serum creatinine (MD = −5.96, 95% CI: −9.27 to −2.65, P = 0.0004) and blood urea nitrogen (MD = −0.91, 95% CI: −1.46 to −0.36, P = 0.001). The total effective rate was higher in the experimental group (OR = 5.10, 95% CI: 3.38 to 7.68, P < 0.00001), though this outcome should be interpreted with caution due to the lack of blinding and the subjective nature of the indicator. Adverse events were reported in only 6 of the 11 studies; the experimental group had 12/287 (4.2%) cases and the control group had 12/277 (4.3%) cases, with most reported events being mild to moderate. The pooled analysis showed no significant difference between groups (OR = 0.99, 95% CI: 0.43 to 2.30, P = 0.99), and most reported events were mild to moderate. However, incomplete safety reporting limits the reliability of this finding. Liuwei Dihuang Pills (Decoction) combined with conventional Western medicine may provide additional benefits for patients with early diabetic nephropathy, showing potential advantages in improving objective renal function indicators and clinical outcomes. The available safety data suggest no significant increase in adverse events, but this finding is limited by incomplete reporting across the included studies. Due to the limited sample size, insufficient methodological quality (including lack of allocation concealment and blinding), and high heterogeneity in some analyses, and incomplete adverse event reporting, the overall evidence quality is low. High-quality, large-sample, multi-center RCTs with rigorous methodological design and standardized safety reporting are still needed to further verify the above conclusions. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261280431, identifier: CRD420261280431.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.